The company's focus is on developing  therapies that address significant unmet medical needs in oncology, autoimmune diseases, metabolic disorders, and other serious conditions. Its R&D pipeline includes over twenty novel candidates across various modalities, including monoclonal antibodies, multi-specific antibodies, T cell engagers, and antibody-drug conjugates (ADCs).